ARDX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -55.52% compared to Ardelyx's net margin of 4.8%. Ardelyx's return on equity of -34.68% beat Baxter International's return on equity of -7.38%.

Ardelyx has a consensus price target of $10.32, signalling upside risk potential of 146.85%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 22.94%. Given that Ardelyx has higher upside potential than Baxter International, analysts believe Ardelyx is more attractive than Baxter International.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.92% to investors and pays a quarterly dividend of $0.17 per share. Ardelyx pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than Baxter International quarterly revenues of $2.6B. Ardelyx's net income of -$41.1M is lower than Baxter International's net income of $126M. Notably, Ardelyx's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.73x versus 1.36x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

BridgeBio Pharma has a net margin of -55.52% compared to Ardelyx's net margin of -143.55%. Ardelyx's return on equity of -34.68% beat BridgeBio Pharma's return on equity of --.

Ardelyx has a consensus price target of $10.32, signalling upside risk potential of 146.85%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 74.36%. Given that Ardelyx has higher upside potential than BridgeBio Pharma, analysts believe Ardelyx is more attractive than BridgeBio Pharma.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than BridgeBio Pharma quarterly revenues of $116.6M. Ardelyx's net income of -$41.1M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Ardelyx's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.73x versus 49.98x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -55.52% compared to Ardelyx's net margin of -276.42%. Ardelyx's return on equity of -34.68% beat Insmed's return on equity of -1146.32%.

Ardelyx has a consensus price target of $10.32, signalling upside risk potential of 146.85%. On the other hand Insmed has an analysts' consensus of $96.78 which suggests that it could grow by 41.27%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Insmed has a beta of 0.837, suggesting its less volatile than the S&P 500 by 16.28%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than Insmed quarterly revenues of $92.8M. Ardelyx's net income of -$41.1M is higher than Insmed's net income of -$256.6M. Notably, Ardelyx's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.73x versus 30.94x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of -55.52% compared to Ardelyx's net margin of 3.45%. Ardelyx's return on equity of -34.68% beat Repligen's return on equity of -1.16%.

Ardelyx has a consensus price target of $10.32, signalling upside risk potential of 146.85%. On the other hand Repligen has an analysts' consensus of $183.13 which suggests that it could grow by 43.53%. Given that Ardelyx has higher upside potential than Repligen, analysts believe Ardelyx is more attractive than Repligen.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Repligen has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.699%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are smaller than Repligen quarterly revenues of $169.2M. Ardelyx's net income of -$41.1M is lower than Repligen's net income of $5.8M. Notably, Ardelyx's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.73x versus 11.04x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.